{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:37:07Z","timestamp":1792705027003,"version":"4.5.0"},"reference-count":268,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1038\/s41571-019-0319-9","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T16:08:38Z","timestamp":1581955718000},"page":"313-326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Harnessing cancer immunotherapy during the unexploited immediate perioperative period"],"prefix":"10.1038","volume":"17","author":[{"given":"Pini","family":"Matzner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sandbank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Neeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oded","family":"Zmora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya","family":"Gottumukkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3832-0678","authenticated-orcid":false,"given":"Shamgar","family":"Ben-Eliyahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"319_CR1","unstructured":"Pudner, R. in Nursing the Surgical Patient 3rd edn 17\u201334 (Elsevier, 2010)."},{"key":"319_CR2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrclinonc.2014.224","volume":"12","author":"M Horowitz","year":"2015","unstructured":"Horowitz, M., Neeman, E., Sharon, E. & Ben-Eliyahu, S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat. Rev. Clin. Oncol. 12, 213\u2013226 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"319_CR3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrclinonc.2017.194","volume":"15","author":"JG Hiller","year":"2018","unstructured":"Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B. & Sloan, E. K. Perioperative events influence cancer recurrence risk after surgery. Nat. Rev. Clin. Oncol. 15, 205\u2013218 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"319_CR4","first-page":"343","volume":"4","author":"J Weitz","year":"1998","unstructured":"Weitz, J. et al. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin. Cancer Res. 4, 343\u2013348 (1998).","journal-title":"Clin. Cancer Res."},{"key":"319_CR5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11102-011-0308-1","volume":"14","author":"ME Sughrue","year":"2011","unstructured":"Sughrue, M. E., Chang, E. F., Gabriel, R. A., Aghi, M. K. & Blevins, L. S. Excess mortality for patients with residual disease following resection of pituitary adenomas. Pituitary 14, 276\u2013283 (2011).","journal-title":"Pituitary"},{"key":"319_CR6","first-page":"1951","volume":"28","author":"R Caprotti","year":"2008","unstructured":"Caprotti, R. et al. Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery. Anticancer Res. 28, 1951\u20131954 (2008).","journal-title":"Anticancer Res."},{"key":"319_CR7","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2010.33.0738","volume":"29","author":"R Badwe","year":"2011","unstructured":"Badwe, R. et al. Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. J. Clin. Oncol. 29, 2845\u20132851 (2011).","journal-title":"J. Clin. Oncol."},{"key":"319_CR8","first-page":"599","volume":"26","author":"F Brivio","year":"2006","unstructured":"Brivio, F. et al. Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B\u2013C. Anticancer Res. 26, 599\u2013603 (2006).","journal-title":"Anticancer Res."},{"key":"319_CR9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2217\/fon-2017-0635","volume":"14","author":"R Haldar","year":"2018","unstructured":"Haldar, R. & Ben-Eliyahu, S. Reducing the risk of post-surgical cancer recurrence: a perioperative anti-inflammatory anti-stress approach. Future Oncol. 14, 1017\u20131021 (2018).","journal-title":"Future Oncol."},{"key":"319_CR10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cncr.31594","volume":"125","author":"I Ricon","year":"2019","unstructured":"Ricon, I., Hanalis-Miller, T., Haldar, R., Jacoby, R. & Ben-Eliyahu, S. Perioperative biobehavioral interventions to prevent cancer recurrence through combined inhibition of \u03b2-adrenergic and cyclooxygenase 2 signaling. Cancer 125, 45\u201356 (2019).","journal-title":"Cancer"},{"key":"319_CR11","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1158\/1078-0432.CCR-12-1087","volume":"18","author":"E Neeman","year":"2012","unstructured":"Neeman, E., Zmora, O. & Ben-Eliyahu, S. A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins. Clin. Cancer Res. 18, 4895\u20134902 (2012).","journal-title":"Clin. Cancer Res."},{"key":"319_CR12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bbi.2016.05.017","volume":"58","author":"L Sorski","year":"2016","unstructured":"Sorski, L. et al. Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through \u03b2-adrenoceptors blockade and COX2 inhibition. Brain Behav. Immun. 58, 91\u201398 (2016).","journal-title":"Brain Behav. Immun."},{"key":"319_CR13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/SLA.0b013e31826fcbdb","volume":"258","author":"R Seth","year":"2013","unstructured":"Seth, R. et al. Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving natural killer cells in a murine model. Ann. Surg. 258, 158\u2013168 (2013).","journal-title":"Ann. Surg."},{"key":"319_CR14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1158\/0008-5472.CAN-12-1993","volume":"73","author":"LH Tai","year":"2013","unstructured":"Tai, L. H. et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res. 73, 97\u2013107 (2013).","journal-title":"Cancer Res."},{"key":"319_CR15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.surge.2010.07.011","volume":"9","author":"BV Hogan","year":"2011","unstructured":"Hogan, B. V., Peter, M. B., Shenoy, H. G., Horgan, K. & Hughes, T. A. Surgery induced immunosuppression. Surgeon 9, 38\u201343 (2011).","journal-title":"Surgeon"},{"key":"319_CR16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bbi.2006.12.006","volume":"21","author":"K Greenfeld","year":"2007","unstructured":"Greenfeld, K. et al. Immune suppression while awaiting surgery and following it: dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav. Immun. 21, 503\u2013513 (2007).","journal-title":"Brain Behav. Immun."},{"key":"319_CR17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev.pa.35.040195.002221","volume":"35","author":"KS Madden","year":"1995","unstructured":"Madden, K. S., Sanders, V. M. & Felten, D. L. Catecholamine influences and sympathetic neural modulation of immune responsiveness. Annu. Rev. Pharmacol. Toxicol. 35, 417\u2013448 (1995).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"319_CR18","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S1471-4906(03)00173-X","volume":"24","author":"DA Padgett","year":"2003","unstructured":"Padgett, D. A. & Glaser, R. How stress influences the immune response. Trends Immunol. 24, 444\u2013448 (2003).","journal-title":"Trends Immunol."},{"key":"319_CR19","doi-asserted-by":"crossref","first-page":"S650","DOI":"10.1245\/s10434-013-3136-x","volume":"20","author":"P Forget","year":"2013","unstructured":"Forget, P. et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann. Surg. Oncol. 20, S650\u2013S660 (2013).","journal-title":"Ann. Surg. Oncol."},{"key":"319_CR20","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/bja\/aex225","volume":"119","author":"JP Cata","year":"2017","unstructured":"Cata, J. P., Guerra, C. E., Chang, G. J., Gottumukkala, V. & Joshi, G. P. Non-steroidal anti-inflammatory drugs in the oncological surgical population: beneficial or harmful? A systematic review of the literature. Br. J. Anaesth. 119, 750\u2013764 (2017).","journal-title":"Br. J. Anaesth."},{"key":"319_CR21","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/00000542-199909000-00026","volume":"91","author":"S Ben-Eliyahu","year":"1999","unstructured":"Ben-Eliyahu, S., Shakhar, G., Rosenne, E., Levinson, Y. & Beilin, B. Hypothermia in barbiturate-anesthetized rats suppresses natural killer cell activity and compromises resistance to tumor metastasis: a role for adrenergic mechanisms. Anesthesiology 91, 732\u2013740 (1999).","journal-title":"Anesthesiology"},{"key":"319_CR22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/00000542-199811000-00013","volume":"89","author":"B Beilin","year":"1998","unstructured":"Beilin, B. et al. Effects of mild perioperative hypothermia on cellular immune responses. Anesthesiology 89, 1133\u20131140 (1998).","journal-title":"Anesthesiology"},{"key":"319_CR23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/neu.1999.16.225","volume":"16","author":"M Aibiki","year":"1999","unstructured":"Aibiki, M. et al. Effect of moderate hypothermia on systemic and internal jugular plasma IL-6 levels after traumatic brain injury in humans. J. Neurotrauma 16, 225\u2013232 (1999).","journal-title":"J. Neurotrauma"},{"key":"319_CR24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/bjs.1800820505","volume":"82","author":"HJ Nielsen","year":"1995","unstructured":"Nielsen, H. J. Detrimental effects of perioperative blood-transfusion. Br. J. Surg. 82, 582\u2013587 (1995).","journal-title":"Br. J. Surg."},{"key":"319_CR25","first-page":"187","volume":"82","author":"DF Landers","year":"1996","unstructured":"Landers, D. F., Hill, G. E., Wong, K. C. & Fox, I. J. Blood transfusion-induced immunomodulation. Anesth. Analg. 82, 187\u2013204 (1996).","journal-title":"Anesth. Analg."},{"key":"319_CR26","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/bja\/aes421","volume":"109","author":"A Heaney","year":"2012","unstructured":"Heaney, A. & Buggy, D. J. Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br. J. Anaesth. 109, i17\u2013i28 (2012).","journal-title":"Br. J. Anaesth."},{"key":"319_CR27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00262-011-1161-9","volume":"61","author":"P Filipazzi","year":"2012","unstructured":"Filipazzi, P., Huber, V. & Rivoltini, L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol. Immunother. 61, 255\u2013263 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"319_CR28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14, 399\u2013416 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"319_CR29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/imm.12036","volume":"138","author":"D Lindau","year":"2013","unstructured":"Lindau, D., Gielen, P., Kroesen, M., Wesseling, P. & Adema, G. J. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138, 105\u2013115 (2013).","journal-title":"Immunology"},{"key":"319_CR30","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00418-008-0530-8","volume":"130","author":"G Lorusso","year":"2008","unstructured":"Lorusso, G. & Rugg, C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol. 130, 1091\u20131103 (2008).","journal-title":"Histochem. Cell Biol."},{"key":"319_CR31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/emmm.200900043","volume":"1","author":"JM Lopez-Novoa","year":"2009","unstructured":"Lopez-Novoa, J. M. & Nieto, M. A. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol. Med. 1, 303\u2013314 (2009).","journal-title":"EMBO Mol. Med."},{"key":"319_CR32","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798\u2013809 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"319_CR33","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549\u2013555 (2002).","journal-title":"Trends Immunol."},{"key":"319_CR34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrc3978","volume":"15","author":"SW Cole","year":"2015","unstructured":"Cole, S. W., Nagaraja, A. S., Lutgendorf, S. K., Green, P. A. & Sood, A. K. Sympathetic nervous system regulation of the tumour microenvironment. Nat. Rev. Cancer 15, 563\u2013572 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"319_CR35","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1158\/1078-0432.CCR-17-0152","volume":"23","author":"L Shaashua","year":"2017","unstructured":"Shaashua, L. et al. Perioperative COX-2 and \u03b2-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial. Clin. Cancer Res. 23, 4651\u20134661 (2017).","journal-title":"Clin. Cancer Res."},{"key":"319_CR36","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrc2256","volume":"7","author":"JAModels Aguirre-Ghiso","year":"2007","unstructured":"Aguirre-Ghiso, J. A. Models Mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834\u2013846 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"319_CR37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg816","volume":"3","author":"PA Jones","year":"2002","unstructured":"Jones, P. A. & Baylin, S. B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415\u2013428 (2002).","journal-title":"Nat. Rev. Genet."},{"key":"319_CR38","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","volume":"168","author":"AW Lambert","year":"2017","unstructured":"Lambert, A. W., Pattabiraman, D. R. & Weinberg, R. A. Emerging biological principles of metastasis. Cell 168, 670\u2013691 (2017).","journal-title":"Cell"},{"key":"319_CR39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0065-2776(06)90002-9","volume":"90","author":"CG Drake","year":"2006","unstructured":"Drake, C. G., Jaffee, E. & Pardoll, D. M. Mechanisms of immune evasion by tumors. Adv. Immunol. 90, 51\u201381 (2006).","journal-title":"Adv. Immunol."},{"key":"319_CR40","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/bjs.5054","volume":"92","author":"CS McArdle","year":"2005","unstructured":"McArdle, C. S., McMillan, D. C. & Hole, D. J. Impact of anastomotic leakage on long-term survival of patients undergoing curative resection for colorectal cancer. Br. J. Surg. 92, 1150\u20131154 (2005).","journal-title":"Br. J. Surg."},{"key":"319_CR41","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/cncr.25573","volume":"117","author":"JP Erinjeri","year":"2011","unstructured":"Erinjeri, J. P. et al. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer 117, 1296\u20131301 (2011).","journal-title":"Cancer"},{"key":"319_CR42","volume":"8","author":"WG Payne","year":"2008","unstructured":"Payne, W. G. et al. Wound healing in patients with cancer. Eplasty 8, e9 (2008).","journal-title":"Eplasty"},{"key":"319_CR43","first-page":"428169","volume":"2015","author":"M Guan","year":"2015","unstructured":"Guan, M., Zhou, Y. P., Sun, J. L. & Chen, S. C. Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res. Int. 2015, 428169 (2015).","journal-title":"Biomed Res. Int."},{"key":"319_CR44","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/1097-0142(197510)36:4<1277::AID-CNCR2820360413>3.0.CO;2-1","volume":"36","author":"SC Cohen","year":"1975","unstructured":"Cohen, S. C., Gabelnick, H. L., Johnson, R. K. & Goldin, A. Effects of cyclophosphamide and adriamycin on the healing of surgical wounds in mice. Cancer 36, 1277\u20131281 (1975).","journal-title":"Cancer"},{"key":"319_CR45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000474042","volume":"9","author":"U Engelmann","year":"1983","unstructured":"Engelmann, U., Grimm, K., Gronniger, J., Burger, R. & Jacobi, G. H. Influence of cis-platinum on healing of enterostomies in the rat. Eur. Urol. 9, 45\u201349 (1983).","journal-title":"Eur. Urol."},{"key":"319_CR46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00000658-196603000-00001","volume":"163","author":"JF Newcombe","year":"1966","unstructured":"Newcombe, J. F. & Chir, M. Effect of intra-arterial nitrogen mustard infusion on wound healing in rabbits\u2014formation of granulation tissue and wound contraction. Ann. Surg. 163, 319\u2013329 (1966).","journal-title":"Ann. Surg."},{"key":"319_CR47","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/1097-0142(197806)41:6<2088::AID-CNCR2820410604>3.0.CO;2-J","volume":"41","author":"R Nissen-Meyer","year":"1978","unstructured":"Nissen-Meyer, R., Kjellgren, K., Malmio, K., Mansson, B. & Norin, T. Surgical adjuvant chemotherapy: results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 41, 2088\u20132098 (1978).","journal-title":"Cancer"},{"key":"319_CR48","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF02482319","volume":"29","author":"AY Arikan","year":"1999","unstructured":"Arikan, A. Y., Senel, F. M., Akman, R. Y. & Can, C. Comparison of the effects of various anticancer agents on intestinal anastomosis after intraperitoneal administration. Surg. Today 29, 741\u2013746 (1999).","journal-title":"Surg. Today"},{"key":"319_CR49","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3171\/jns.1973.39.3.0315","volume":"39","author":"J Garfield","year":"1973","unstructured":"Garfield, J. & Dayan, A. D. Postoperative intracavitary chemotherapy of malignant gliomas\u2014preliminary study using methotrexate. J. Neurosurg. 39, 315\u2013322 (1973).","journal-title":"J. Neurosurg."},{"key":"319_CR50","first-page":"1201","volume":"127","author":"I Cohn","year":"1968","unstructured":"Cohn, I., Slack, N. H. & Fisher, B. Complications and toxic manifestations of surgical adjuvant chemotherapy for breast cancer. Surg. Gynecol. Obstet. 127, 1201\u20131209 (1968).","journal-title":"Surg. Gynecol. Obstet."},{"key":"319_CR51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1289\/ehp.824321","volume":"43","author":"L Rasmussen","year":"1982","unstructured":"Rasmussen, L. & Arvin, A. Chemotherapy-induced immunosuppression. Environ. Health Perspect. 43, 21\u201325 (1982).","journal-title":"Environ. Health Perspect."},{"key":"319_CR52","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/1097-0142(197602)37:2+<1058::AID-CNCR2820370813>3.0.CO;2-O","volume":"37","author":"J Harris","year":"1976","unstructured":"Harris, J., Sengar, D., Stewart, T. & Hyslop, D. The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer 37, 1058\u20131069 (1976).","journal-title":"Cancer"},{"key":"319_CR53","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28, 690\u2013714 (2015).","journal-title":"Cancer Cell"},{"key":"319_CR54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel, L., Apetoh, L., Ghiringhelli, F. & Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59\u201373 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"319_CR55","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1158\/0008-5472.CAN-13-3596","volume":"74","author":"ZC Ding","year":"2014","unstructured":"Ding, Z. C. et al. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1\u2013PD-L1 axis. Cancer Res. 74, 3441\u20133453 (2014).","journal-title":"Cancer Res."},{"key":"319_CR56","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.nutres.2007.09.001","volume":"27","author":"YW Tsang","year":"2007","unstructured":"Tsang, Y. W. et al. Chemotherapy-induced immunosuppression is restored by a fermented soybean extract: a proof of concept clinical trial. Nutr. Res. 27, 679\u2013684 (2007).","journal-title":"Nutr. Res."},{"key":"319_CR57","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/NNR.0b013e31818fcecd","volume":"58","author":"DH Kang","year":"2009","unstructured":"Kang, D. H. et al. Significant impairment in immune recovery after cancer treatment. Nurs. Res. 58, 105\u2013114 (2009).","journal-title":"Nurs. Res."},{"key":"319_CR58","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-015-0669-x","volume":"18","author":"R Verma","year":"2016","unstructured":"Verma, R. et al. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res. 18, 10 (2016).","journal-title":"Breast Cancer Res."},{"key":"319_CR59","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel, J. Breakthrough of the year 2013. Cancer immunotherapy. Science 342, 1432\u20131433 (2013).","journal-title":"Science"},{"key":"319_CR60","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.3390\/cancers3043856","volume":"3","author":"S Lee","year":"2011","unstructured":"Lee, S. & Margolin, K. Cytokines in cancer immunotherapy. Cancers 3, 3856\u20133893 (2011).","journal-title":"Cancers"},{"key":"319_CR61","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1189\/jlb.1012501","volume":"93","author":"S Kaczanowska","year":"2013","unstructured":"Kaczanowska, S., Joseph, A. M. & Davila, E. TLR agonists: our best frenemy in cancer immunotherapy. J. Leukoc. Biol. 93, 847\u2013863 (2013).","journal-title":"J. Leukoc. Biol."},{"key":"319_CR62","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"319_CR63","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.cgt.7700538","volume":"9","author":"MJ Mastrangelo","year":"2002","unstructured":"Mastrangelo, M. J. & Lattime, E. C. Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Cancer Gene Ther. 9, 1013\u20131021 (2002).","journal-title":"Cancer Gene Ther."},{"key":"319_CR64","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.it.2004.01.008","volume":"25","author":"KA Gelderman","year":"2004","unstructured":"Gelderman, K. A., Tomlinson, S., Ross, G. D. & Gorter, A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 25, 158\u2013164 (2004).","journal-title":"Trends Immunol."},{"key":"319_CR65","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1158\/1078-0432.CCR-11-1107","volume":"17","author":"TR Sippel","year":"2011","unstructured":"Sippel, T. R. et al. Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin. Cancer Res. 17, 6992\u20137002 (2011).","journal-title":"Clin. Cancer Res."},{"key":"319_CR66","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123\u2013135 (2015).","journal-title":"N. Engl. J. Med."},{"key":"319_CR67","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540\u20131550 (2016).","journal-title":"Lancet"},{"key":"319_CR68","first-page":"CD001425","volume":"12","author":"C Coppin","year":"2005","unstructured":"Coppin, C. et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 12, CD001425 (2005).","journal-title":"Cochrane Database Syst. Rev."},{"key":"319_CR69","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"319_CR70","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 4","key":"319_CR71","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1200\/JCO.2019.37.4_suppl.2","volume":"37","author":"T Kojima","year":"2019","unstructured":"Kojima, T. et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. J. Clin. Oncol. 37 (Suppl. 4), 2-2 (2019).","journal-title":"J. Clin. Oncol."},{"key":"319_CR72","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627\u20131639 (2015).","journal-title":"N. Engl. J. Med."},{"key":"319_CR73","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1093\/annonc\/mdv361","volume":"26","author":"MS Carlino","year":"2015","unstructured":"Carlino, M. S. & Long, G. V. Is chemotherapy still an option in the treatment of melanoma? Ann. Oncol. 26, 2203\u20132204 (2015).","journal-title":"Ann. Oncol."},{"key":"319_CR74","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134\u2013144 (2013).","journal-title":"N. Engl. J. Med."},{"key":"319_CR75","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/00003246-199609000-00002","volume":"24","author":"J Cohen","year":"1996","unstructured":"Cohen, J. & Carlet, J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-\u03b1 in patients with sepsis. International Sepsis Trial Study Group. Crit. Care Med. 24, 1431\u20131440 (1996).","journal-title":"Crit. Care Med."},{"key":"319_CR76","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/leu.2008.214","volume":"22","author":"JE Castro","year":"2008","unstructured":"Castro, J. E., Sandoval-Sus, J. D., Bole, J., Rassenti, L. & Kipps, T. J. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 22, 2048\u20132053 (2008).","journal-title":"Leukemia"},{"key":"319_CR77","first-page":"228","volume":"78","author":"U Wolters","year":"1997","unstructured":"Wolters, U., Wolf, T., St\u00fctzer, H. & Schr\u00f6der, T. ASA classification and perioperative variables as predictors of postoperative outcome. Br. J. Anaesth. 78, 228\u2013228 (1997).","journal-title":"Br. J. Anaesth."},{"key":"319_CR78","unstructured":"National Cancer Institute. Find NCI-supported clinical trials. NCI https:\/\/www.cancer.gov\/about-cancer\/treatment\/clinical-trials\/search (2020)."},{"key":"319_CR79","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ (2020)."},{"key":"319_CR80","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","volume":"4","author":"JW Pollard","year":"2004","unstructured":"Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71\u201378 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"319_CR81","first-page":"919","volume":"72","author":"MR Young","year":"1984","unstructured":"Young, M. R. & Knies, S. Prostaglandin E production by Lewis lung carcinoma: mechanism for tumor establishment in vivo. J. Natl Cancer Inst. 72, 919\u2013922 (1984).","journal-title":"J. Natl Cancer Inst."},{"key":"319_CR82","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","volume":"21","author":"GL Beatty","year":"2015","unstructured":"Beatty, G. L. & Gladney, W. L. Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res. 21, 687\u2013692 (2015).","journal-title":"Clin. Cancer Res."},{"key":"319_CR83","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991\u2013998 (2002).","journal-title":"Nat. Immunol."},{"key":"319_CR84","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423\u20131437 (2013).","journal-title":"Nat. Med."},{"key":"319_CR85","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nm1469","volume":"12","author":"PS Steeg","year":"2006","unstructured":"Steeg, P. S. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 12, 895\u2013904 (2006).","journal-title":"Nat. Med."},{"key":"319_CR86","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.surg.2013.02.002","volume":"153","author":"OM Rashid","year":"2013","unstructured":"Rashid, O. M. et al. Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Surgery 153, 771\u2013778 (2013).","journal-title":"Surgery"},{"key":"319_CR87","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"319_CR88","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","volume":"63","author":"W Lasek","year":"2014","unstructured":"Lasek, W., Zagozdzon, R. & Jakobisiak, M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol. Immunother. 63, 419\u2013435 (2014).","journal-title":"Cancer Immunol. Immunother."},{"key":"319_CR89","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nm1589","volume":"13","author":"H Kanzler","year":"2007","unstructured":"Kanzler, H., Barrat, F. J., Hessel, E. M. & Coffman, R. L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13, 552\u2013559 (2007).","journal-title":"Nat. Med."},{"key":"319_CR90","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1245\/s10434-013-3088-1","volume":"20","author":"L Marano","year":"2013","unstructured":"Marano, L. et al. Clinical and immunological impact of early postoperative enteral immunonutrition after total gastrectomy in gastric cancer patients: a prospective randomized study. Ann. Surg. Oncol. 20, 3912\u20133918 (2013).","journal-title":"Ann. Surg. Oncol."},{"key":"319_CR91","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.cji.0000211304.60126.8f","volume":"29","author":"BK Link","year":"2006","unstructured":"Link, B. K. et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. 29, 558\u2013568 (2006).","journal-title":"J. Immunother."},{"key":"319_CR92","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/hyb.1999.18.41","volume":"18","author":"S Reinartz","year":"1999","unstructured":"Reinartz, S. et al. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines\u2014a preliminary report. Hybridoma 18, 41\u201345 (1999).","journal-title":"Hybridoma"},{"key":"319_CR93","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/SLA.0b013e318211d7b5","volume":"253","author":"Y Goldfarb","year":"2011","unstructured":"Goldfarb, Y. et al. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann. Surg. 253, 798\u2013810 (2011).","journal-title":"Ann. Surg."},{"key":"319_CR94","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.4049\/jimmunol.0903301","volume":"184","author":"A Glasner","year":"2010","unstructured":"Glasner, A. et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a \u03b2-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J. Immunol. 184, 2449\u20132457 (2010).","journal-title":"J. Immunol."},{"key":"319_CR95","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/ijc.29885","volume":"138","author":"P Matzner","year":"2016","unstructured":"Matzner, P. et al. Perioperative treatment with the new synthetic TLR-4 agonist GLA-SE reduces cancer metastasis without adverse effects. Int. J. Cancer 138, 1754\u20131764 (2016).","journal-title":"Int. J. Cancer"},{"key":"319_CR96","doi-asserted-by":"crossref","first-page":"eaar1916","DOI":"10.1126\/scitranslmed.aar1916","volume":"10","author":"CG Park","year":"2018","unstructured":"Park, C. G. et al. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci. Transl Med. 10, eaar1916 (2018).","journal-title":"Sci. Transl Med."},{"key":"319_CR97","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1158\/1078-0432.CCR-13-0246","volume":"19","author":"LH Tai","year":"2013","unstructured":"Tai, L. H. et al. Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells. Clin. Cancer Res. 19, 5104\u20135115 (2013).","journal-title":"Clin. Cancer Res."},{"key":"319_CR98","volume":"2","author":"LH Tai","year":"2013","unstructured":"Tai, L. H., Zhang, J. Q. & Auer, R. C. Preventing surgery-induced NK cell dysfunction and cancer metastases with influenza vaccination. Oncoimmunology 2, e26618 (2013).","journal-title":"Oncoimmunology"},{"key":"319_CR99","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri1806","volume":"6","author":"W Zou","year":"2006","unstructured":"Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295\u2013307 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"319_CR100","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s12272-012-0802-7","volume":"35","author":"S Basith","year":"2012","unstructured":"Basith, S., Manavalan, B., Yoo, T. H., Kim, S. G. & Choi, S. Roles of Toll-like receptors in cancer: a double-edged sword for defense and offense. Arch. Pharm. Res. 35, 1297\u20131316 (2012).","journal-title":"Arch. Pharm. Res."},{"key":"319_CR101","volume":"48","author":"IS Hong","year":"2016","unstructured":"Hong, I. S. Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. Exp. Mol. Med. 48, e242 (2016).","journal-title":"Exp. Mol. Med."},{"key":"319_CR102","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.molimm.2007.01.022","volume":"44","author":"W He","year":"2007","unstructured":"He, W. et al. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol. Immunol. 44, 2850\u20132859 (2007).","journal-title":"Mol. Immunol."},{"key":"319_CR103","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1158\/0008-5472.CAN-05-3948","volume":"66","author":"MG Kelly","year":"2006","unstructured":"Kelly, M. G. et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 66, 3859\u20133868 (2006).","journal-title":"Cancer Res."},{"key":"319_CR104","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/blood.V73.1.80.80","volume":"73","author":"WE Berdel","year":"1989","unstructured":"Berdel, W. E., Danhauserriedl, S., Steinhauser, G. & Winton, E. F. Various human hematopoietic growth-factors (interleukin-3, GM-CSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor-cells. Blood 73, 80\u201383 (1989).","journal-title":"Blood"},{"key":"319_CR105","doi-asserted-by":"crossref","first-page":"9253","DOI":"10.1073\/pnas.85.23.9253","volume":"85","author":"S Dedhar","year":"1988","unstructured":"Dedhar, S., Gaboury, L., Galloway, P. & Eaves, C. Human granulocyte\u2013macrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhemopoietic origin. Proc. Natl Acad. Sci. USA 85, 9253\u20139257 (1988).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"319_CR106","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ijc.11188","volume":"106","author":"S Ninck","year":"2003","unstructured":"Ninck, S. et al. Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int. J. Cancer 106, 34\u201344 (2003).","journal-title":"Int. J. Cancer"},{"key":"319_CR107","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bbi.2016.02.025","volume":"56","author":"B Levi","year":"2016","unstructured":"Levi, B. et al. Stress impairs the efficacy of immune stimulation by CpG-C: potential neuroendocrine mediating mechanisms and significance to tumor metastasis and the perioperative period. Brain Behav. Immun. 56, 209\u2013220 (2016).","journal-title":"Brain Behav. Immun."},{"key":"319_CR108","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28440","volume":"3","author":"T Nagato","year":"2014","unstructured":"Nagato, T. & Celis, E. A novel combinatorial cancer immunotherapy poly-IC and blockade of the PD-1\/PD-L1 pathway. Oncoimmunology 3, e28440 (2014).","journal-title":"Oncoimmunology"},{"key":"319_CR109","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.bbi.2019.03.005","volume":"80","author":"P Matzner","year":"2019","unstructured":"Matzner, P. et al. Deleterious synergistic effects of distress and surgery on cancer metastasis: abolishment through an integrated perioperative immune-stimulating stress-inflammatory-reducing intervention. Brain Behav. Immun. 80, 170\u2013178 (2019).","journal-title":"Brain Behav. Immun."},{"key":"319_CR110","first-page":"13","volume":"11","author":"A Zambouri","year":"2007","unstructured":"Zambouri, A. Preoperative evaluation and preparation for anesthesia and surgery. Hippokratia 11, 13\u201321 (2007).","journal-title":"Hippokratia"},{"key":"319_CR111","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.jacc.2014.07.944","volume":"64","author":"LA Fleisher","year":"2014","unstructured":"Fleisher, L. A. et al. 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. 64, e77\u2013e137 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"319_CR112","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/SLA.0b013e31827b6bbc","volume":"257","author":"S Kwon","year":"2013","unstructured":"Kwon, S. et al. Importance of perioperative glycemic control in general surgery: a report from the surgical care and outcomes assessment program. Ann. Surg. 257, 8\u201314 (2013).","journal-title":"Ann. Surg."},{"key":"319_CR113","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1499-3872(14)60267-8","volume":"13","author":"PL Ge","year":"2014","unstructured":"Ge, P. L., Du, S. D. & Mao, Y. L. Advances in preoperative assessment of liver function. Hepatobiliary Pancreat. Dis. Int. 13, 361\u2013370 (2014).","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"319_CR114","first-page":"387","volume":"62","author":"MS King","year":"2000","unstructured":"King, M. S. Preoperative evaluation. Am. Fam. Physician 62, 387\u2013396 (2000).","journal-title":"Am. Fam. Physician"},{"key":"319_CR115","unstructured":"Tinker, J. H. et al. Recommendations and Guidelines for Preoperative Evaluation of the Surgical Patient with Emphasis on the Cardiac Patient for Non-Cardiac Surgery (University of Nebraska Medical Center, 2006)."},{"key":"319_CR116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/000313481207800102","volume":"78","author":"DE Fry","year":"2012","unstructured":"Fry, D. E. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am. Surg. 78, 1\u20138 (2012).","journal-title":"Am. Surg."},{"key":"319_CR117","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/TA.0b013e318265cf87","volume":"73","author":"PE Marik","year":"2012","unstructured":"Marik, P. E. & Flemmer, M. The immune response to surgery and trauma: implications for treatment. J. Trauma Acute Care 73, 801\u2013808 (2012).","journal-title":"J. Trauma Acute Care"},{"key":"319_CR118","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/ncb1500","volume":"8","author":"J Lee","year":"2006","unstructured":"Lee, J. et al. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat. Cell Biol. 8, 1327\u20131336 (2006).","journal-title":"Nat. Cell Biol."},{"key":"319_CR119","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nri2873","volume":"10","author":"GY Chen","year":"2010","unstructured":"Chen, G. Y. & Nunez, G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10, 826\u2013837 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"319_CR120","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1054\/bjoc.2001.2076","volume":"85","author":"J Atzpodien","year":"2001","unstructured":"Atzpodien, J. et al. IL-2 in combination with IFN-\u03b1 and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br. J. Cancer 85, 1130\u20131136 (2001).","journal-title":"Br. J. Cancer"},{"key":"319_CR121","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2007.12.5807","volume":"26","author":"C Manegold","year":"2008","unstructured":"Manegold, C. et al. Randomized phase II trial of a Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26, 3979\u20133986 (2008).","journal-title":"J. Clin. Oncol."},{"key":"319_CR122","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1080\/14712598.2016.1234602","volume":"16","author":"C Gridelli","year":"2016","unstructured":"Gridelli, C. et al. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian Association of Thoracic Oncology. Expert Opin. Biol. Ther. 16, 1479\u20131489 (2016).","journal-title":"Expert Opin. Biol. Ther."},{"key":"319_CR123","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","volume":"13","author":"A Bertrand","year":"2015","unstructured":"Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M. E. & Schaeverbeke, T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 13, 211 (2015).","journal-title":"BMC Med."},{"key":"319_CR124","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/bja\/85.1.109","volume":"85","author":"JP Desborough","year":"2000","unstructured":"Desborough, J. P. The stress response to trauma and surgery. Br. J. Anaesth. 85, 109\u2013117 (2000).","journal-title":"Br. J. Anaesth."},{"key":"319_CR125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbi.2010.07.242","volume":"25","author":"Y Goldfarb","year":"2011","unstructured":"Goldfarb, Y., Levi, B., Sorski, L., Frenkel, D. & Ben-Eliyahu, S. CpG-C immunotherapeutic efficacy is jeopardized by ongoing exposure to stress: potential implications for clinical use. Brain Behav. Immun. 25, 67\u201376 (2011).","journal-title":"Brain Behav. Immun."},{"key":"319_CR126","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/glia.22804","volume":"63","author":"S Biesmans","year":"2015","unstructured":"Biesmans, S. et al. Effect of stress and peripheral immune activation on astrocyte activation in transgenic bioluminescent Gfap-luc mice. Glia 63, 1126\u20131137 (2015).","journal-title":"Glia"},{"key":"319_CR127","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/npp.2016.90","volume":"42","author":"C Menard","year":"2017","unstructured":"Menard, C., Pfau, M. L., Hodes, G. E. & Russo, S. J. Immune and neuroendocrine mechanisms of stress vulnerability and resilience. Neuropsychopharmacology 42, 62\u201380 (2017).","journal-title":"Neuropsychopharmacology"},{"key":"319_CR128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2006859","volume":"17","author":"A Benbenishty","year":"2019","unstructured":"Benbenishty, A. et al. Prophylactic TLR9 stimulation reduces brain metastasis through microglia activation. PLoS Biol. 17, e2006859 (2019).","journal-title":"PLoS Biol."},{"key":"319_CR129","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bbi.2018.05.014","volume":"73","author":"R Haldar","year":"2018","unstructured":"Haldar, R. et al. Perioperative inhibition of \u03b2-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. Brain Behav. Immun. 73, 294\u2013309 (2018).","journal-title":"Brain Behav. Immun."},{"key":"319_CR130","first-page":"488","volume":"23","author":"S Bhatia","year":"2009","unstructured":"Bhatia, S., Tykodi, S. S. & Thompson, J. A. Treatment of metastatic melanoma: an overview. Oncology 23, 488\u2013496 (2009).","journal-title":"Oncology"},{"key":"319_CR131","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1025389031000091167","volume":"6","author":"S Hayley","year":"2003","unstructured":"Hayley, S., Merali, Z. & Anisman, H. Stress and cytokine-elicited neuroendocrine and neurotransmitter sensitization: implications for depressive illness. Stress 6, 19\u201332 (2003).","journal-title":"Stress"},{"key":"319_CR132","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneuroim.2007.02.008","volume":"186","author":"H Anisman","year":"2007","unstructured":"Anisman, H., Poulter, M. O., Gandhi, R., Merali, Z. & Hayley, S. Interferon-\u03b1 effects are exaggerated when administered on a psychosocial stressor backdrop: cytokine, corticosterone and brain monoamine variations. J. Neuroimmunol. 186, 45\u201353 (2007).","journal-title":"J. Neuroimmunol."},{"key":"319_CR133","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1017\/S1461145702003152","volume":"5","author":"Y Pollak","year":"2002","unstructured":"Pollak, Y. & Yirmiya, R. Cytokine-induced changes in mood and behaviour: implications for \u201cdepression due to a general medical condition\u201d, immunotherapy and antidepressive treatment. Int. J. Neuropsychopharmacol. 5, 389\u2013399 (2002).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"319_CR134","first-page":"113","volume":"6","author":"P Lissoni","year":"1992","unstructured":"Lissoni, P. et al. Inhibitory effect of interleukin-3 on interleukin-2-induced cortisol release in the immunotherapy of cancer. J. Biol. Regul. Homeost. Agents 6, 113\u2013115 (1992).","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"319_CR135","first-page":"R652","volume":"276","author":"MJ Lenczowski","year":"1999","unstructured":"Lenczowski, M. J. et al. Central administration of rat IL-6 induces HPA activation and fever but not sickness behavior in rats. Am. J. Physiol. 276, R652\u2013R658 (1999).","journal-title":"Am. J. Physiol."},{"key":"319_CR136","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.bbi.2010.12.012","volume":"25","author":"DG Bernabe","year":"2011","unstructured":"Bernabe, D. G., Tamae, A. C., Biasoli, E. R. & Oliveira, S. H. Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells. Brain Behav. Immun. 25, 574\u2013583 (2011).","journal-title":"Brain Behav. Immun."},{"key":"319_CR137","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-1-4615-1951-5_29","volume":"373","author":"D Saphier","year":"1995","unstructured":"Saphier, D. Neuroendocrine effects of interferon-\u03b1 in the rat. Adv. Exp. Med. Biol. 373, 209\u2013218 (1995).","journal-title":"Adv. Exp. Med. Biol."},{"key":"319_CR138","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0014-2999(93)90588-9","volume":"236","author":"D Saphier","year":"1993","unstructured":"Saphier, D., Welch, J. E. & Chuluyan, H. E. \u03b1-Interferon inhibits adrenocortical secretion via Mu 1-opioid receptors in the rat. Eur. J. Pharmacol. 236, 183\u2013191 (1993).","journal-title":"Eur. J. Pharmacol."},{"key":"319_CR139","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0306-4530(01)00099-3","volume":"27","author":"MU Goebel","year":"2002","unstructured":"Goebel, M. U. et al. Acute interferon \u03b21b administration alters hypothalamic\u2013pituitary\u2013adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects. Psychoneuroendocrinology 27, 881\u2013892 (2002).","journal-title":"Psychoneuroendocrinology"},{"key":"319_CR140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0024-3205(88)90617-0","volume":"42","author":"F Holsboer","year":"1988","unstructured":"Holsboer, F. et al. Acute adrenocortical stimulation by recombinant \u03b3-interferon in human controls. Life Sci. 42, 1\u20135 (1988).","journal-title":"Life Sci."},{"key":"319_CR141","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1182\/blood-2010-05-282913","volume":"116","author":"Y Lepelletier","year":"2010","unstructured":"Lepelletier, Y. et al. Toll-like receptor control of glucocorticoid-induced apoptosis in human plasmacytoid predendritic cells (pDCs). Blood 116, 3389\u20133397 (2010).","journal-title":"Blood"},{"key":"319_CR142","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.vaccine.2015.10.027","volume":"34","author":"M Santini-Oliveira","year":"2016","unstructured":"Santini-Oliveira, M. et al. Schistosomiasis vaccine candidate Sm14\/GLA-SE: phase 1 safety and immunogenicity clinical trial in healthy, male adults. Vaccine 34, 586\u2013594 (2016).","journal-title":"Vaccine"},{"key":"319_CR143","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2013.08.064","volume":"31","author":"JJ Treanor","year":"2013","unstructured":"Treanor, J. J. et al. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5\/Indonesia\/05\/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE plus GLA) adjuvant. Vaccine 31, 5760\u20135765 (2013).","journal-title":"Vaccine"},{"key":"319_CR144","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/nat.2012.0340","volume":"22","author":"AM Krieg","year":"2012","unstructured":"Krieg, A. M. CpG still rocks! Update on an accidental drug. Nucleic Acid. Ther. 22, 77\u201389 (2012).","journal-title":"Nucleic Acid. Ther."},{"key":"319_CR145","doi-asserted-by":"crossref","first-page":"E87","DOI":"10.1016\/j.suronc.2012.01.002","volume":"21","author":"Y Zhang","year":"2012","unstructured":"Zhang, Y., Gu, Y. H., Guo, T. K., Li, Y. P. & Cai, H. Perioperative immunonutrition for gastrointestinal cancer: a systematic review of randomized controlled trials. Surg. Oncol. 21, E87\u2013E95 (2012).","journal-title":"Surg. Oncol."},{"key":"319_CR146","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1079\/BJN2002682","volume":"88","author":"PC Calder","year":"2002","unstructured":"Calder, P. C. & Kew, S. The immune system: a target for functional foods? Br. J. Nutr. 88, S165\u2013S176 (2002).","journal-title":"Br. J. Nutr."},{"key":"319_CR147","unstructured":"Nestl\u00e9 Health Science. Impact. Nestl\u00e9 https:\/\/www.nestlehealthscience.com\/brands\/impact\/impact (2019)."},{"key":"319_CR148","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.amjsurg.2011.12.018","volume":"204","author":"K Caglayan","year":"2012","unstructured":"Caglayan, K. et al. The impact of preoperative immunonutrition and other nutrition models on tumor infiltrative lymphocytes in colorectal cancer patients. Am. J. Surg. 204, 416\u2013421 (2012).","journal-title":"Am. J. Surg."},{"key":"319_CR149","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/lary.20494","volume":"119","author":"LD Sorensen","year":"2009","unstructured":"Sorensen, L. D., McCarthy, M., Baumgartner, M. B. & Demars, C. S. Perioperative immunonutrition in head and neck cancer. Laryngoscope 119, 1358\u20131364 (2009).","journal-title":"Laryngoscope"},{"key":"319_CR150","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3390\/nu5041186","volume":"5","author":"A Turnock","year":"2013","unstructured":"Turnock, A. et al. Perioperative immunonutrition in well-nourished patients undergoing surgery for head and neck cancer: evaluation of inflammatory and immunologic outcomes. Nutrients 5, 1186\u20131199 (2013).","journal-title":"Nutrients"},{"key":"319_CR151","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1001\/archsurg.134.4.428","volume":"134","author":"M Braga","year":"1999","unstructured":"Braga, M. et al. Perioperative immunonutrition in patients undergoing cancer surgery\u2014results of a randomized double-blind phase 3 trial. Arch. Surg. 134, 428\u2013433 (1999).","journal-title":"Arch. Surg."},{"key":"319_CR152","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.amjmed.2004.12.024","volume":"118","author":"PJ Mazzone","year":"2005","unstructured":"Mazzone, P. J. & Arroliga, A. C. Lung cancer: preoperative pulmonary evaluation of the lung resection candidate. Am. J. Med. 118, 578\u2013583 (2005).","journal-title":"Am. J. Med."},{"key":"319_CR153","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1378\/chest.104.3.694","volume":"104","author":"SK Epstein","year":"1993","unstructured":"Epstein, S. K., Faling, L. J., Daly, B. D. T. & Celli, B. R. Predicting complications after pulmonary resection \u2014preoperative exercise testing vs a multifactorial cardiopulmonary risk index. Chest 104, 694\u2013700 (1993).","journal-title":"Chest"},{"key":"319_CR154","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1365-2044.2009.05983.x","volume":"64","author":"TB Smith","year":"2009","unstructured":"Smith, T. B., Stonell, C., Purkayastha, S. & Paraskevas, P. Cardiopulmonary exercise testing as a risk assessment method in non cardio-pulmonary surgery: a systematic review. Anaesthesia 64, 883\u2013893 (2009).","journal-title":"Anaesthesia"},{"key":"319_CR155","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/bja\/aet408","volume":"112","author":"MA West","year":"2014","unstructured":"West, M. A. et al. Cardiopulmonary exercise variables are associated with postoperative morbidity after major colonic surgery: a prospective blinded observational study. Br. J. Anaesth. 112, 665\u2013671 (2014).","journal-title":"Br. J. Anaesth."},{"key":"319_CR156","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/bjs.10112","volume":"103","author":"MA West","year":"2016","unstructured":"West, M. A. et al. Validation of preoperative cardiopulmonary exercise testing-derived variables to predict in-hospital morbidity after major colorectal surgery. Br. J. Surg. 103, 744\u2013752 (2016).","journal-title":"Br. J. Surg."},{"key":"319_CR157","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/jama.2011.513","volume":"305","author":"T Morikawa","year":"2011","unstructured":"Morikawa, T. et al. Association of CTNNB1 (\u03b2-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 305, 1685\u20131694 (2011).","journal-title":"JAMA"},{"key":"319_CR158","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1200\/JCO.2006.06.0855","volume":"24","author":"JA Meyerhardt","year":"2006","unstructured":"Meyerhardt, J. A. et al. Physical activity and survival after colorectal cancer diagnosis. J. Clin. Oncol. 24, 3527\u20133534 (2006).","journal-title":"J. Clin. Oncol."},{"key":"319_CR159","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/gut.2005.068189","volume":"55","author":"AMM Haydon","year":"2006","unstructured":"Haydon, A. M. M., MacInnis, R. J., English, D. R. & Giles, G. G. Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 55, 62\u201367 (2006).","journal-title":"Gut"},{"key":"319_CR160","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1200\/JCO.2005.06.085","volume":"23","author":"DA Galvao","year":"2005","unstructured":"Galvao, D. A. & Newton, R. U. Review of exercise intervention studies in cancer patients. J. Clin. Oncol. 23, 899\u2013909 (2005).","journal-title":"J. Clin. Oncol."},{"key":"319_CR161","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1600-0838.2010.01288.x","volume":"22","author":"J Wang","year":"2012","unstructured":"Wang, J. et al. Effect of exercise training intensity on murine T-regulatory cells and vaccination response. Scand. J. Med. Sci. Sports 22, 643\u2013652 (2012).","journal-title":"Scand. J. Med. Sci. Sports"},{"key":"319_CR162","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/acm.2011.0593","volume":"19","author":"RT Ho","year":"2013","unstructured":"Ho, R. T. et al. The effect of t\u2019ai chi exercise on immunity and infections: a systematic review of controlled trials. J. Altern. Complement. Med. 19, 389\u2013396 (2013).","journal-title":"J. Altern. Complement. Med."},{"key":"319_CR163","volume":"8","author":"ME Bote","year":"2013","unstructured":"Bote, M. E., Garcia, J. J., Hinchado, M. D. & Ortega, E. Fibromyalgia: anti-inflammatory and stress responses after acute moderate exercise. PLoS One 8, e74524 (2013).","journal-title":"PLoS One"},{"key":"319_CR164","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc1252","volume":"4","author":"G Dranoff","year":"2004","unstructured":"Dranoff, G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4, 11\u201322 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"319_CR165","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.4049\/jimmunol.135.4.2865","volume":"135","author":"MT Lotze","year":"1985","unstructured":"Lotze, M. T. et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. 135, 2865\u20132875 (1985).","journal-title":"J. Immunol."},{"key":"319_CR166","volume":"5","author":"T Jiang","year":"2016","unstructured":"Jiang, T., Zhou, C. & Ren, S. Role of IL-2 in cancer immunotherapy. Oncoimmunology 5, e1163462 (2016).","journal-title":"Oncoimmunology"},{"key":"319_CR167","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0748-7983(05)80061-7","volume":"21","author":"DJ Deehan","year":"1995","unstructured":"Deehan, D. J., Heys, S. D., Ashby, J. & Eremin, O. Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease. Eur. J. Surg. Oncol. 21, 16\u201322 (1995).","journal-title":"Eur. J. Surg. Oncol."},{"key":"319_CR168","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/sj.bjc.6603391","volume":"95","author":"T Klatte","year":"2006","unstructured":"Klatte, T. et al. Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial. Br. J. Cancer 95, 1167\u20131173 (2006).","journal-title":"Br. J. Cancer"},{"key":"319_CR169","first-page":"5765","volume":"52","author":"PH Nichols","year":"1992","unstructured":"Nichols, P. H., Ramsden, C. W., Ward, U., Sedman, P. C. & Primrose, J. N. Perioperative immunotherapy with recombinant interleukin-2 in patients undergoing surgery for colorectal-cancer. Cancer Res. 52, 5765\u20135769 (1992).","journal-title":"Cancer Res."},{"key":"319_CR170","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/bjs.1800751012","volume":"75","author":"PC Sedman","year":"1988","unstructured":"Sedman, P. C., Ramsden, C. W., Brennan, T. G., Giles, G. R. & Guillou, P. J. Effects of low-dose perioperative interferon on the surgically induced suppression of antitumour immune-responses. Br. J. Surg. 75, 976\u2013981 (1988).","journal-title":"Br. J. Surg."},{"key":"319_CR171","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000112214","volume":"31","author":"T Klatte","year":"2008","unstructured":"Klatte, T. et al. Pretreatment with interferon-\u03b12a modulates perioperative immunodysfunction in patients with renal cell carcinoma. Onkologie 31, 28\u201334 (2008).","journal-title":"Onkologie"},{"key":"319_CR172","first-page":"172","volume":"54","author":"H Nagano","year":"2007","unstructured":"Nagano, H. et al. Hepatic resection followed by IFN-\u03b1 and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepatogastroenterology 54, 172\u2013179 (2007).","journal-title":"Hepatogastroenterology"},{"key":"319_CR173","first-page":"5429","volume":"53","author":"S Cascinu","year":"1993","unstructured":"Cascinu, S. et al. Cytokinetic effects of interferon in colorectal-cancer tumors\u2014implications in the design of the interferon\/5-fluorouracil combinations. Cancer Res. 53, 5429\u20135432 (1993).","journal-title":"Cancer Res."},{"key":"319_CR174","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0022-5347(05)64556-9","volume":"168","author":"P Rajala","year":"2002","unstructured":"Rajala, P. et al. Perioperative single dose instillation of epirubicin or interferon-\u03b1 after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study\u2014Finnbladder III long-term results. J. Urol. 168, 981\u2013985 (2002).","journal-title":"J. Urol."},{"key":"319_CR175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/01.sla.0000103062.21049.82","volume":"239","author":"C Schneider","year":"2004","unstructured":"Schneider, C. et al. Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann. Surg. 239, 75\u201381 (2004).","journal-title":"Ann. Surg."},{"key":"319_CR176","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1365-2168.2001.01722.x","volume":"88","author":"AK Mels","year":"2001","unstructured":"Mels, A. K. et al. Immune-stimulating effects of low-dose perioperative recombinant granulocyte\u2013macrophage colony-stimulating factor in patients operated on for primary colorectal carcinoma. Br. J. Surg. 88, 539\u2013544 (2001).","journal-title":"Br. J. Surg."},{"key":"319_CR177","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1089\/107999003321532484","volume":"23","author":"AK Licht","year":"2003","unstructured":"Licht, A. K., Schinkel, C., Zedler, S., Schinkel, S. & Faist, E. Effects of perioperative recombinant human IFN-\u03b3 (rHuIFN-\u03b3) application in vivo on T cell response. J. Interferon Cytokine Res. 23, 149\u2013154 (2003).","journal-title":"J. Interferon Cytokine Res."},{"key":"319_CR178","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/0140-6736(91)92927-T","volume":"337","author":"RA Badwe","year":"1991","unstructured":"Badwe, R. A. et al. Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 337, 1261\u20131264 (1991).","journal-title":"Lancet"},{"key":"319_CR179","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2125.1994.tb04308.x","volume":"37","author":"NM Wheeldon","year":"1994","unstructured":"Wheeldon, N. M. et al. Influence of sex-steroid hormones on the regulation of lymphocyte \u03b22-adrenoceptors during the menstrual cycle. Br. J. Clin. Pharmacol. 37, 583\u2013588 (1994).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"319_CR180","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/bjc.1996.651","volume":"74","author":"S Ben-Eliyahu","year":"1996","unstructured":"Ben-Eliyahu, S., Page, G. G., Shakhar, G. & Taylor, A. N. Increased susceptibility to metastasis during pro-oestrus\/oestrus in rats: possible role of oestradiol and natural killer cells. Br. J. Cancer 74, 1900\u20131907 (1996).","journal-title":"Br. J. Cancer"},{"key":"319_CR181","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1054\/bjoc.2000.1490","volume":"83","author":"K Shakhar","year":"2000","unstructured":"Shakhar, K., Shakhar, G., Rosenne, E. & Ben-Eliyahu, S. Timing within the menstrual cycle, sex, and the use of oral contraceptives determine adrenergic suppression of NK cell activity. Br. J. Cancer 83, 1630\u20131636 (2000).","journal-title":"Br. J. Cancer"},{"key":"319_CR182","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1054\/bjoc.2000.1563","volume":"83","author":"S Ben-Eliyahu","year":"2000","unstructured":"Ben-Eliyahu, S., Shakhar, G., Shakhar, K. & Melamed, R. Timing within the oestrous cycle modulates adrenergic suppression of NK activity and resistance to metastasis: possible clinical implications. Br. J. Cancer 83, 1747\u20131754 (2000).","journal-title":"Br. J. Cancer"},{"key":"319_CR183","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/A:1005826403235","volume":"45","author":"GG Page","year":"1997","unstructured":"Page, G. G. & Ben-Eliyahu, S. Increased surgery-induced metastasis and suppressed natural killer cell activity during proestrus\/estrus in rats. Breast Cancer Res. Treat. 45, 159\u2013167 (1997).","journal-title":"Breast Cancer Res. Treat."},{"key":"319_CR184","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.bbi.2012.03.006","volume":"30","author":"E Neeman","year":"2013","unstructured":"Neeman, E. & Ben-Eliyahu, S. Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav. Immun. 30, S32\u2013S40 (2013).","journal-title":"Brain Behav. Immun."},{"key":"319_CR185","unstructured":"Haldar, R., Ricon, I., Cole, S., Zmora, O. and Ben-Eliyahu, S. Perioperative \u03b2-adrenergic blockade and COX2 inhibition in colorectal cancer patients improves pro-metastatic indices in the excised tumor: EMT, tumor infiltrating lymphocytes (TILs), and gene regulatory pathways. Presented at the PNIRS 24th Annual Scientific Meeting (2017)."},{"key":"319_CR186","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5414\/CP201550","volume":"49","author":"O Hazut","year":"2011","unstructured":"Hazut, O. et al. The effect of \u03b2-adrenergic blockade and COX-2 inhibition on healing of colon, muscle, and skin in rats undergoing colonic anastomosis. Int. J. Clin. Pharmacol. Ther. 49, 545\u2013554 (2011).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"319_CR187","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00384-010-0992-8","volume":"25","author":"B Benjamin","year":"2010","unstructured":"Benjamin, B. et al. Effect of \u03b2 blocker combined with COX-2 inhibitor on colonic anastomosis in rats. Int. J. Colorectal Dis. 25, 1459\u20131464 (2010).","journal-title":"Int. J. Colorectal Dis."},{"key":"319_CR188","doi-asserted-by":"crossref","first-page":"eaan0026","DOI":"10.1126\/scitranslmed.aan0026","volume":"9","author":"GS Karagiannis","year":"2017","unstructured":"Karagiannis, G. S. et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Sci. Transl Med. 9, eaan0026 (2017).","journal-title":"Sci. Transl Med."},{"key":"319_CR189","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.bbi.2010.03.010","volume":"24","author":"R Avraham","year":"2010","unstructured":"Avraham, R. et al. Synergism between immunostimulation and prevention of surgery-induced immune suppression: an approach to reduce post-operative tumor progression. Brain Behav. Immun. 24, 952\u2013958 (2010).","journal-title":"Brain Behav. Immun."},{"key":"319_CR190","first-page":"374","volume":"108","author":"IJ Elenkov","year":"1996","unstructured":"Elenkov, I. J., Papanicolaou, D. A., Wilder, R. L. & Chrousos, G. P. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc. Assoc. Am. Physicians 108, 374\u2013381 (1996).","journal-title":"Proc. Assoc. Am. Physicians"},{"key":"319_CR191","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1042\/bj2720327","volume":"272","author":"MM Whalen","year":"1990","unstructured":"Whalen, M. M. & Bankhurst, A. D. Effects of \u03b2-adrenergic receptor activation, cholera toxin and forskolin on human natural killer cell function. Biochem. J. 272, 327\u2013331 (1990).","journal-title":"Biochem. J."},{"key":"319_CR192","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000054276","volume":"8","author":"S Ben-Eliyahu","year":"2000","unstructured":"Ben-Eliyahu, S., Shakhar, G., Page, G. G., Stefanski, V. & Shakhar, K. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and \u03b2-adrenoceptors. Neuroimmunomodulation 8, 154\u2013164 (2000).","journal-title":"Neuroimmunomodulation"},{"key":"319_CR193","first-page":"113","volume":"28","author":"T Diamantstein","year":"1975","unstructured":"Diamantstein, T. & Ulmer, A. Antagonistic action of cyclic-GMP and cyclic-AMP on proliferation of B and T lymphocytes. Immunology 28, 113\u2013119 (1975).","journal-title":"Immunology"},{"key":"319_CR194","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nri1810","volume":"6","author":"EM Sternberg","year":"2006","unstructured":"Sternberg, E. M. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol. 6, 318\u2013328 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"319_CR195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0165-5728(98)00231-8","volume":"94","author":"R Sacedon","year":"1999","unstructured":"Sacedon, R., Vicente, A., Varas, A., Jimenez, E. & Zapata, A. G. Early differentiation of thymic dendritic cells in the absence of glucocorticoids. J. Neuroimmunol. 94, 103\u2013108 (1999).","journal-title":"J. Neuroimmunol."},{"key":"319_CR196","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.psyneuen.2013.12.001","volume":"42","author":"L Shaashua","year":"2014","unstructured":"Shaashua, L. et al. Plasma IL-12 levels are suppressed in vivo by stress and surgery through endogenous release of glucocorticoids and prostaglandins but not catecholamines or opioids. Psychoneuroendocrinology 42, 11\u201323 (2014).","journal-title":"Psychoneuroendocrinology"},{"key":"319_CR197","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1126\/science.270.5234.283","volume":"270","author":"RI Scheinman","year":"1995","unstructured":"Scheinman, R. I., Cogswell, P. C., Lofquist, A. K. & Baldwin, A. S. Role of transcriptional activation of I\u03baB\u03b1in mediation of immunosuppression by glucocorticoids. Science 270, 283\u2013286 (1995).","journal-title":"Science"},{"key":"319_CR198","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/(SICI)1521-4141(200004)30:4<1233::AID-IMMU1233>3.0.CO;2-F","volume":"30","author":"MK Matyszak","year":"2000","unstructured":"Matyszak, M. K., Citterio, S., Rescigno, M. & Ricciardi-Castagnoli, P. Differential effects of corticosteroids during different stages of dendritic cell maturation. Eur. J. Immunol. 30, 1233\u20131242 (2000).","journal-title":"Eur. J. Immunol."},{"key":"319_CR199","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.4049\/jimmunol.175.3.1483","volume":"175","author":"F Baratelli","year":"2005","unstructured":"Baratelli, F. et al. Prostaglandin E-2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J. Immunol. 175, 1483\u20131490 (2005).","journal-title":"J. Immunol."},{"key":"319_CR200","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/0008-5472.CAN-05-0141","volume":"65","author":"S Sharma","year":"2005","unstructured":"Sharma, S. et al. Tumor cyclooxygenase-2\/prostaglandin E-2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Res. 65, 5211\u20135220 (2005).","journal-title":"Cancer Res."},{"key":"319_CR201","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4049\/jimmunol.164.1.361","volume":"164","author":"M Stolina","year":"2000","unstructured":"Stolina, M. et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164, 361\u2013370 (2000).","journal-title":"J. Immunol."},{"key":"319_CR202","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ejca.2006.01.003","volume":"42","author":"A Sica","year":"2006","unstructured":"Sica, A., Schioppa, T., Mantovani, A. & Allavena, P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42, 717\u2013727 (2006).","journal-title":"Eur. J. Cancer"},{"key":"319_CR203","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1172\/JCI16492","volume":"111","author":"L Yang","year":"2003","unstructured":"Yang, L. et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest. 111, 727\u2013735 (2003).","journal-title":"J. Clin. Invest."},{"key":"319_CR204","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1213\/01.ANE.0000082995.44040.07","volume":"97","author":"R Melamed","year":"2003","unstructured":"Melamed, R., Bar-Yosef, S., Shakhar, G., Shakhar, K. & Ben-Eliyahu, S. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesth. Analg. 97, 1331\u20131339 (2003).","journal-title":"Anesth. Analg."},{"key":"319_CR205","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/00000542-199304000-00013","volume":"78","author":"SN Markovic","year":"1993","unstructured":"Markovic, S. N., Knight, P. R. & Murasko, D. M. Inhibition of interferon stimulation of natural killer cell activity in mice anesthetized with halothane or isoflurane. Anesthesiology 78, 700\u2013706 (1993).","journal-title":"Anesthesiology"},{"key":"319_CR206","doi-asserted-by":"crossref","first-page":"R645","DOI":"10.1186\/bcr1036","volume":"7","author":"RA Siddiqui","year":"2005","unstructured":"Siddiqui, R. A. et al. Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells. Breast Cancer Res. 7, R645\u2013R654 (2005).","journal-title":"Breast Cancer Res."},{"key":"319_CR207","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1213\/01.ane.0000198330.84341.35","volume":"102","author":"M Sakaguchi","year":"2006","unstructured":"Sakaguchi, M., Kuroda, Y. & Hirose, M. The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor. Anesth. Analg. 102, 1103\u20131107 (2006).","journal-title":"Anesth. Analg."},{"key":"319_CR208","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/jcp.10145","volume":"192","author":"T Mammoto","year":"2002","unstructured":"Mammoto, T. et al. Infiltration anesthetic lidocaine inhibits cancer cell invasion by modulating ectodomain shedding of heparin-binding epidermal growth factor-like growth factor (HB-EGF). J. Cell. Physiol. 192, 351\u2013358 (2002).","journal-title":"J. Cell. Physiol."},{"key":"319_CR209","first-page":"660","volume":"288","author":"T Martinsson","year":"1999","unstructured":"Martinsson, T. Ropivacaine inhibits serum-induced proliferation of colon adenocarcinoma cells in vitro. J. Pharmacol. Exp. Ther. 288, 660\u2013664 (1999).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"319_CR210","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cct.2008.01.002","volume":"29","author":"DI Sessler","year":"2008","unstructured":"Sessler, D. I., Ben-Eliyahu, S., Mascha, E. J., Parat, M. O. & Buggy, D. J. Can regional analgesia reduce the risk of recurrence after breast cancer? Methodology of a multicenter randomized trial. Contemp. Clin. Trials 29, 517\u2013526 (2008).","journal-title":"Contemp. Clin. Trials"},{"key":"319_CR211","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/infdis\/159.3.480","volume":"159","author":"PK Peterson","year":"1989","unstructured":"Peterson, P. K. et al. Suppression of human peripheral-blood mononuclear cell-function by methadone and morphine. J. Infect. Dis. 159, 480\u2013487 (1989).","journal-title":"J. Infect. Dis."},{"key":"319_CR212","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0192-0561(93)90057-6","volume":"15","author":"CC Chao","year":"1993","unstructured":"Chao, C. C., Molitor, T. W., Close, K., Hu, S. X. & Peterson, P. K. Morphine inhibits the release of tumor-necrosis-factor in human peripheral-blood mononuclear cell-cultures. Int. J. Immunopharmacol. 15, 447\u2013453 (1993).","journal-title":"Int. J. Immunopharmacol."},{"key":"319_CR213","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10555-011-9285-0","volume":"30","author":"B Afsharimani","year":"2011","unstructured":"Afsharimani, B., Cabot, P. & Parat, M. O. Morphine and tumor growth and metastasis. Cancer Metastasis Rev. 30, 225\u2013238 (2011).","journal-title":"Cancer Metastasis Rev."},{"key":"319_CR214","first-page":"1179","volume":"264","author":"DJJ Carr","year":"1993","unstructured":"Carr, D. J. J., Gebhardt, B. M. & Paul, D. \u03b1-Adrenergic and Mu-2 opioid receptors are involved in morphine-induced suppression of splenocyte natural-killer activity. J. Pharmacol. Exp. Ther. 264, 1179\u20131186 (1993).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"319_CR215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0165-5728(94)90064-7","volume":"53","author":"DJ Carr","year":"1994","unstructured":"Carr, D. J., Mayo, S., Gebhardt, B. M. & Porter, J. Central \u03b1-adrenergic involvement in morphine-mediated suppression of splenic natural killer activity. J. Neuroimmunol. 53, 53\u201363 (1994).","journal-title":"J. Neuroimmunol."},{"key":"319_CR216","first-page":"1127","volume":"270","author":"DO Freier","year":"1994","unstructured":"Freier, D. O. & Fuchs, B. A. A mechanism of action for morphine-induced immunosuppression: corticosterone mediates morphine-induced suppression of natural killer cell activity. J. Pharmacol. Exp. Ther. 270, 1127\u20131133 (1994).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"319_CR217","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/sj.bjp.0701138","volume":"121","author":"P Sacerdote","year":"1997","unstructured":"Sacerdote, P., Manfredi, B., Mantegazza, P. & Panerai, A. E. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br. J. Pharmacol. 121, 834\u2013840 (1997).","journal-title":"Br. J. Pharmacol."},{"key":"319_CR218","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/0024-3205(93)90122-J","volume":"53","author":"M Rojavin","year":"1993","unstructured":"Rojavin, M. et al. Morphine treatment in-vitro or in-vivo decreases phagocytic functions of murine macrophages. Life Sci. 53, 997\u20131006 (1993).","journal-title":"Life Sci."},{"key":"319_CR219","doi-asserted-by":"crossref","DOI":"10.1038\/srep31572","volume":"6","author":"S Khabbazi","year":"2016","unstructured":"Khabbazi, S., Nassar, Z. D., Goumon, Y. & Parat, M. O. Morphine decreases the pro-angiogenic interaction between breast cancer cells and macrophages in vitro. Sci. Rep. 6, 31572 (2016).","journal-title":"Sci. Rep."},{"key":"319_CR220","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0165-5728(95)00159-X","volume":"64","author":"C Alicea","year":"1996","unstructured":"Alicea, C., Belkowski, S., Eisenstein, T. K., Adler, M. W. & Rogers, T. J. Inhibition of primary murine macrophage cytokine production in vitro following treatment with the \u03ba-opioid agonist U50,488H. J. Neuroimmunol. 64, 83\u201390 (1996).","journal-title":"J. Neuroimmunol."},{"key":"319_CR221","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/00001813-200410000-00002","volume":"15","author":"DN Wheatley","year":"2004","unstructured":"Wheatley, D. N. Controlling cancer by restricting arginine availability\u2014arginine-catabolizing enzymes as anticancer. Anticancer Drugs 15, 825\u2013833 (2004).","journal-title":"Anticancer Drugs"},{"key":"319_CR222","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1517\/13543784.15.7.815","volume":"15","author":"L Feun","year":"2006","unstructured":"Feun, L. & Savaraj, N. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin. Investig. Drugs 15, 815\u2013822 (2006).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"319_CR223","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1200\/JCO.2004.11.120","volume":"22","author":"F Izzo","year":"2004","unstructured":"Izzo, F. et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I\/II studies. J. Clin. Oncol. 22, 1815\u20131822 (2004).","journal-title":"J. Clin. Oncol."},{"key":"319_CR224","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.clnu.2008.10.007","volume":"28","author":"S Nanthakumaran","year":"2009","unstructured":"Nanthakumaran, S., Brown, I., Heys, S. D. & Schofield, A. C. Inhibition of gastric cancer cell growth by arginine: molecular mechanisms of action. Clin. Nutr. 28, 65\u201370 (2009).","journal-title":"Clin. Nutr."},{"key":"319_CR225","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1084\/jem.169.3.1021","volume":"169","author":"JE Albina","year":"1989","unstructured":"Albina, J. E., Caldwell, M. D., Henry, W. L. Jr. & Mills, C. D. Regulation of macrophage functions by L-arginine. J. Exp. Med. 169, 1021\u20131029 (1989).","journal-title":"J. Exp. Med."},{"key":"319_CR226","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0140-6736(91)92456-C","volume":"337","author":"KG Park","year":"1991","unstructured":"Park, K. G., Hayes, P. D., Garlick, P. J., Sewell, H. & Eremin, O. Stimulation of lymphocyte natural cytotoxicity by L-arginine. Lancet 337, 645\u2013646 (1991).","journal-title":"Lancet"},{"key":"319_CR227","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.6269181","volume":"214","author":"YS Cho-Chung","year":"1981","unstructured":"Cho-Chung, Y. S., Clair, T., Bodwin, J. S. & Berghoffer, B. Growth arrest and morphological change of human breast cancer cells by dibutyryl cyclic AMP and L-arginine. Science 214, 77\u201379 (1981).","journal-title":"Science"},{"key":"319_CR228","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1517\/13543784.2014.934808","volume":"23","author":"A Synakiewicz","year":"2014","unstructured":"Synakiewicz, A., Stachowicz-Stencel, T. & Adamkiewicz-Drozynska, E. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on phase I\/II clinical trials. Expert Opin. Investig. Drugs 23, 1517\u20131529 (2014).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"319_CR229","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1182\/blood.V80.6.1576.1576","volume":"80","author":"D Samid","year":"1992","unstructured":"Samid, D., Yeh, A. & Prasanna, P. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood 80, 1576\u20131581 (1992).","journal-title":"Blood"},{"key":"319_CR230","first-page":"891","volume":"54","author":"D Samid","year":"1994","unstructured":"Samid, D. et al. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res. 54, 891\u2013895 (1994).","journal-title":"Cancer Res."},{"key":"319_CR231","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1172\/JCI116457","volume":"91","author":"D Samid","year":"1993","unstructured":"Samid, D., Shack, S. & Myers, C. E. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest. 91, 2288\u20132295 (1993).","journal-title":"J. Clin. Invest."},{"key":"319_CR232","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/onc.2009.358","volume":"29","author":"RJ DeBerardinis","year":"2010","unstructured":"DeBerardinis, R. J. & Cheng, T. Q\u2019s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29, 313\u2013324 (2010).","journal-title":"Oncogene"},{"key":"319_CR233","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.4049\/jimmunol.176.8.4894","volume":"176","author":"B Salaun","year":"2006","unstructured":"Salaun, B., Coste, I., Rissoan, M. C., Lebecque, S. J. & Renno, T. TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol. 176, 4894\u20134901 (2006).","journal-title":"J. Immunol."},{"key":"319_CR234","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2217\/imt.09.70","volume":"1","author":"S Adams","year":"2009","unstructured":"Adams, S. Toll-like receptor agonists in cancer therapy. Immunotherapy 1, 949\u2013964 (2009).","journal-title":"Immunotherapy"},{"key":"319_CR235","doi-asserted-by":"crossref","first-page":"27252","DOI":"10.18632\/oncotarget.4583","volume":"6","author":"V Ho","year":"2015","unstructured":"Ho, V. et al. TLR3 agonist and sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. Oncotarget 6, 27252\u201327266 (2015).","journal-title":"Oncotarget"},{"key":"319_CR236","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jnci\/57.3.599","volume":"57","author":"RA Robinson","year":"1976","unstructured":"Robinson, R. A. et al. Phase 1\u20132 trial of multiple-dose polyriboinosinic-polyribocytidylic acid in patients with leukemia or solid tumors. J. Natl Cancer Inst. 57, 599\u2013602 (1976).","journal-title":"J. Natl Cancer Inst."},{"key":"319_CR237","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/09680519060120050701","volume":"12","author":"MR Alderson","year":"2006","unstructured":"Alderson, M. R., McGowan, P., Baldridge, J. R. & Probst, P. TLR4 agonists as immunomodulatory agents. J. Endotoxin Res. 12, 313\u2013319 (2006).","journal-title":"J. Endotoxin Res."},{"key":"319_CR238","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016333","volume":"6","author":"RN Coler","year":"2011","unstructured":"Coler, R. N. et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 6, e16333 (2011).","journal-title":"PLoS One"},{"key":"319_CR239","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1158\/0008-5472.CAN-07-5219","volume":"68","author":"N Yusuf","year":"2008","unstructured":"Yusuf, N. et al. Protective role of toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. Cancer Res. 68, 615\u2013622 (2008).","journal-title":"Cancer Res."},{"key":"319_CR240","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.leu.2404061","volume":"20","author":"DE Spaner","year":"2006","unstructured":"Spaner, D. E. et al. Immunomodulatory effects of toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 20, 286\u2013295 (2006).","journal-title":"Leukemia"},{"key":"319_CR241","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1158\/1078-0432.CCR-07-1938","volume":"14","author":"R Dummer","year":"2008","unstructured":"Dummer, R. et al. An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin. Cancer Res. 14, 856\u2013864 (2008).","journal-title":"Clin. Cancer Res."},{"key":"319_CR242","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","volume":"20","author":"AM Krieg","year":"2002","unstructured":"Krieg, A. M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709\u2013760 (2002).","journal-title":"Annu. Rev. Immunol."},{"key":"319_CR243","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd2059","volume":"5","author":"AM Krieg","year":"2006","unstructured":"Krieg, A. M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5, 471\u2013484 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"319_CR244","doi-asserted-by":"crossref","first-page":"9611","DOI":"10.1158\/0008-5472.CAN-10-1968","volume":"70","author":"G Gruenbacher","year":"2010","unstructured":"Gruenbacher, G. et al. IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells. Cancer Res. 70, 9611\u20139620 (2010).","journal-title":"Cancer Res."},{"key":"319_CR245","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2014-07-587493","volume":"124","author":"F Van Gool","year":"2014","unstructured":"Van Gool, F. et al. Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood 124, 3572\u20133576 (2014).","journal-title":"Blood"},{"key":"319_CR246","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nature04790","volume":"441","author":"MA Williams","year":"2006","unstructured":"Williams, M. A., Tyznik, A. J. & Bevan, M. J. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441, 890\u2013893 (2006).","journal-title":"Nature"},{"key":"319_CR247","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ni978","volume":"4","author":"A Le Bon","year":"2003","unstructured":"Le Bon, A. et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4, 1009\u20131015 (2003).","journal-title":"Nat. Immunol."},{"key":"319_CR248","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1084\/jem.147.5.1314","volume":"147","author":"G Trinchieri","year":"1978","unstructured":"Trinchieri, G. & Santoli, D. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells\u2014enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target-cells to lysis. J. Exp. Med. 147, 1314\u20131333 (1978).","journal-title":"J. Exp. Med."},{"key":"319_CR249","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.0105-2896.2004.00207.x","volume":"202","author":"C Bogdan","year":"2004","unstructured":"Bogdan, C., Mattner, J. & Schleicher, U. The role of type I interferons in non-viral infections. Immunol. Rev. 202, 33\u201348 (2004).","journal-title":"Immunol. Rev."},{"key":"319_CR250","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","volume":"25","author":"T Okanoue","year":"1996","unstructured":"Okanoue, T. et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J. Hepatol. 25, 283\u2013291 (1996).","journal-title":"J. Hepatol."},{"key":"319_CR251","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2012.70","volume":"26","author":"S Naik","year":"2012","unstructured":"Naik, S. et al. Curative one-shot systemic virotherapy in murine myeloma. Leukemia 26, 1870\u20131878 (2012).","journal-title":"Leukemia"},{"key":"319_CR252","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nm.2390","volume":"17","author":"T Kottke","year":"2011","unstructured":"Kottke, T. et al. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat. Med. 17, 854\u2013859 (2011).","journal-title":"Nat. Med."},{"key":"319_CR253","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell, S. J., Peng, K. W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658\u2013670 (2012).","journal-title":"Nat. Biotechnol."},{"key":"319_CR254","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka, R. H. I. et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte\u2013macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma. J. Immunother. Cancer 7, 145 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"319_CR255","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","volume":"16","author":"BC Carthon","year":"2010","unstructured":"Carthon, B. C. et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16, 2861\u20132871 (2010).","journal-title":"Clin. Cancer Res."},{"key":"319_CR256","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1074-7613(00)80123-5","volume":"11","author":"P Shrikant","year":"1999","unstructured":"Shrikant, P., Khoruts, A. & Mescher, M. F. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell-and IL-2-dependent mechanism. Immunity 11, 483\u2013493 (1999).","journal-title":"Immunity"},{"key":"319_CR257","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372\u20138377 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"319_CR258","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","volume":"12","author":"CK Lee","year":"2017","unstructured":"Lee, C. K. et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer\u2014a meta-analysis. J. Thorac. Oncol. 12, 403\u2013407 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"319_CR259","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793\u2013800 (2002).","journal-title":"Nat. Med."},{"key":"319_CR260","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi, J. J., Salem, J. E., Sosman, J. A., Lebrun-Vignes, B. & Johnson, D. B. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391, 933 (2018).","journal-title":"Lancet"},{"key":"319_CR261","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/j.jtho.2016.08.110","volume":"11","author":"S Ramalingam","year":"2016","unstructured":"Ramalingam, S. et al. Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab. J. Thorac. Oncol. 11, S241\u2013S242 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"319_CR262","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1182\/blood-2004-07-2959","volume":"105","author":"B Valzasina","year":"2005","unstructured":"Valzasina, B. et al. Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105, 2845\u20132851 (2005).","journal-title":"Blood"},{"key":"319_CR263","first-page":"2501","volume":"110","author":"MD Vu","year":"2007","unstructured":"Vu, M. D. et al. OX40 costimulation turns off Foxp3+ tregs. Blood 110, 2501\u20132510 (2007).","journal-title":"Blood"},{"key":"319_CR264","volume":"8","author":"FY Lei","year":"2013","unstructured":"Lei, F. Y. et al. Regulation of A1 by OX40 contributes to CD8+ T cell survival and anti-tumor activity. PLoS One 8, e70635 (2013).","journal-title":"PLoS One"},{"key":"319_CR265","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.4049\/jimmunol.180.11.7240","volume":"180","author":"JX Song","year":"2008","unstructured":"Song, J. X., So, T. & Croft, M. Activation of NF-\u03baB1 by OX40 contributes to antigen-driven T cell expansion and survival. J. Immunol. 180, 7240\u20137248 (2008).","journal-title":"J. Immunol."},{"key":"319_CR266","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1158\/0008-5472.CAN-12-4174","volume":"73","author":"BD Curti","year":"2013","unstructured":"Curti, B. D. et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73, 7189\u20137198 (2013).","journal-title":"Cancer Res."},{"key":"319_CR267","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.cji.0000211319.00031.fc","volume":"29","author":"AD Weinberg","year":"2006","unstructured":"Weinberg, A. D. et al. Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J. Immunother. 29, 575\u2013585 (2006).","journal-title":"J. Immunother."},{"key":"319_CR268","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.16","volume":"5","author":"R Montler","year":"2016","unstructured":"Montler, R. et al. OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer. Clin. Transl Immunol. 5, e70 (2016).","journal-title":"Clin. Transl Immunol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0319-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0319-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0319-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:52:27Z","timestamp":1695775947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-019-0319-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":268,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1038\/s41571-019-0319-9","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,17]]},"assertion":[{"value":"5 December 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}